Citius Pharmaceuticals, Inc.
corporate_fare Company Profile
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CTXR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 19 rated 8 or above. Recent SEC coverage for CTXR spans 8-K, 10-Q, S-3, 424B5.
Recent high-impact activity:
- Citius Oncology Q4 LYMPHIR Wholesaler Units Jump 120% to 792
- Citius Pharma Gets Nasdaq Extension to Feb 8, 2027 to Regain $1 Bid Compliance
- Citius Pharma Q3 10-Q: $49.4M Loss, Cash Runway to November, Going Concern
- Citius Pharma Posts $7.1M LYMPHIR Revenue, 383 Vial Orders in July
- Citius Oncology Reports 78% QoQ Growth in New Institutions Ordering LYMPHIR
Financial Snapshot
Short Interest & Short Volume
17.76 days to coverFINRA reported short interest of 5,764,914 shares in CTXR as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 17.8 days to cover at its recent average daily volume. On November 20, 2026, 64.1% of CTXR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.